Disease phenotype associations in patients with SSc with or without joint contracture (JC).
| Characteristic | Whole SSc Population, n = 7286 | Patients with Diffuse Cutaneous Subtype, n = 2393 | Patients with Limited Cutaneous Subtype, n = 4210 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| With JC, n = 2264 | Without JC, n = 5022 | p | Stepwise Regression, OR (95% CI) | With JC, n = 1167 | Without JC, n = 1226 | p | Stepwise Regression, OR (95% CI) | With JC, n = 975 | Without JC, n = 3235 | p | Stepwise Regression OR (95% CI) | |
| Age, mean ± SD, yrs | 57 ± 16 | 58 ± 17 | 0.01* | NS | 53 ± 14 | 56 ± 15 | 0.04* | NS | 58 ± 15 | 62 ± 16 | 0.001* | NS |
| Females (%) | 1902 (84) | 4364 (87) | 0.0001* | NS | 932 (80) | 961 (78) | 0.4 | NS | 855 (88) | 2936 (91) | 0.1* | NS |
| Disease duration, mean ± SD, yrs | 11 ± 8 | 9 ± 10 | 0.03* | NS | 6 ± 7 | 9 ± 8 | 0.01* | 0.47 (0.38–0.81) | 10 ± 9 | 12 ± 13 | 0.001* | NS |
| Friction rub, n (%) | 528 (23) | 274 (5) | < 0.0001* | 2.89 (2.39–3.50) | 365 (31) | 121 (10) | < 0.0001* | 3.16 (2.42–4.12) | 133 (14) | 134 (4) | < 0.0001* | 2.67 (1.98–3.61) |
| Synovitis, n (%) | 587 (26) | 604 (12) | < 0.0001* | 1.75 (1.49–2.05) | 302 (26) | 182 (15) | < 0.0001* | 1.53 (1.18–1.98) | 233 (24) | 337 (10) | < 0.0001* | 2.01 (1.68–2.59) |
| Raynaud phenomenon, n (%) | 2172 (96) | 4774 (95) | 0.2 | NS | 1118 (96) | 1170 (95) | 0.9 | NS | 933 (96) | 3106 (96) | 0.1* | NS |
| Digital ulceration, n (%) | 1023 (45) | 1268 (25) | < 0.0001* | 1.93 (1.69–2.19) | 592 (51) | 390 (32) | < 0.0001* | 1.88 (1.54–2.30) | 397 (41) | 798 (25) | < 0.0001* | 1.85 (1.55–2.19) |
| Muscle weakness, n (%) | 868 (38) | 1080 (21) | < 0.0001* | 1.41 (1.22–1.62) | 504 (43) | 358 (29) | < 0.0001* | 1.38 (1.12–1.71) | 300 (31) | 604 (19) | < 0.0001* | 1.47 (1.21–1.79) |
| Pulmonary fibrosis, n (%) | 1050 (46) | 1557 (31) | < 0.0001* | 1.23 (1.08–1.39) | 623 (53) | 594 (48) | 0.02* | NS | 371 (38) | 845 (26) | < 0.0001* | NS |
| Elevated sPAP, n (%) | 715 (32) | 1041 (21) | < 0.001* | 1.38 (1.19–1.58) | 373 (32) | 259 (21) | < 0.0001* | 1.47 (1.17–1.84) | 287 (29) | 665 (21) | < 0.0001* | 1.30 (1.07–1.57) |
| Renal crisis, n (%) | 72 (3) | 88 (2) | 0.0001* | NS | 53 (5) | 48 (4) | 0.5 | NS | 16 (2) | 33 (1) | 0.1* | NS |
| Positive antinuclear antibodies, n (%) | 2103 (93) | 4514 (90) | 0.06* | NS | 1080 (93) | 1091 (89) | 0.03* | NS | 878 (90) | 2985 (92) | 0.9 | NS |
| Positive antitopoisomerease-1 antibodies, n (%) | 975 (43) | 1318 (26) | < 0.0001* | NS | 688 (59) | 629 (51) | 0.0004* | NS | 261 (27) | 597 (18) | < 0.0001* | NS |
| Positive anticentromere antibodies, n (%) | 406 (18) | 1990 (40) | < 0.0001* | 0.56 (0.47–0.66) | 48 (4) | 92 (8) | 0.0009* | 0.59 (0.39–0.90) | 340 (35) | 1711 (53) | < 0.0001* | 0.50 (0.42–0.59) |
| Elevated CPK, n (%) | 239 (11) | 342 (7) | 0.005* | NS | 166 (14) | 128 (10) | 0.007* | NS | 70 (7) | 134 (4) | 0.0001* | NS |
| Elevation of acute-phase reactants, n (%) | 931 (41) | 1222 (24) | < 0.0001* | 1.48 (1.29–1.70) | 547 (47) | 408 (33) | < 0.0001* | 1.49 (1.12–1.82) | 328 (34) | 690 (21) | < 0.0001* | 1.56 (1.30–1.87) |
| Proteinuria, n (%) | 186 (8) | 249 (5) | < 0.0001* | NS | 120 (10) | 93 (8) | 0.02* | NS | 48 (5) | 124 (4) | 0.1* | NS |
NS: not significant; CPK: creatine phosphokinase; sPAP: systolic pulmonary artery pressure.
↵* Variables included for the multivariate stepwise logistic regression analysis.